Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Phase I Reactions: Reductive Reactions01:27

Phase I Reactions: Reductive Reactions

Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low magnetic fields stimulate cardiac mitochondrial bioenergetics with a bell-shaped response: Possibly via a radical pair mechanism.

Computational and structural biotechnology journal·2025
Same author

Heritability in genetic heart disease: the role of genetic background.

Open heart·2019
Same author

Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction.

European journal of heart failure·2018
Same author

Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients.

JACC. Clinical electrophysiology·2018
Same author

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.

Journal of the American College of Cardiology·2018
Same author

Risk Stratification of Type 2 Long-QT Syndrome Mutation Carriers With Normal QTc Interval: The Value of Sex, T-Wave Morphology, and Mutation Type.

Circulation. Arrhythmia and electrophysiology·2018
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Reduction in inappropriate therapy and mortality through ICD programming.

Arthur J Moss1, Claudio Schuger, Christopher A Beck

  • 1Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642-0653, USA. heartajm@heart.rochester.edu

The New England Journal of Medicine
|November 8, 2012
PubMed
Summary
This summary is machine-generated.

New implantable cardioverter-defibrillator (ICD) programming strategies significantly reduce inappropriate shocks and all-cause mortality. These advanced ICD therapies offer improved patient outcomes compared to conventional programming.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Experiment Videos

Last Updated: May 17, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Trials

Background:

  • Implantable cardioverter-defibrillators (ICDs) effectively reduce mortality in patients at risk for fatal arrhythmias.
  • However, inappropriate ICD activations are common and can lead to adverse effects.
  • Optimizing ICD programming is crucial for patient safety and treatment efficacy.

Purpose of the Study:

  • To evaluate the impact of novel ICD programming configurations on inappropriate therapy occurrences.
  • To compare programmed high-rate therapy and delayed therapy against conventional ICD programming.
  • To assess the effect of these programming strategies on all-cause mortality.

Main Methods:

  • A randomized trial involving 1500 patients with primary-prevention ICD indications.
  • Three programming configurations were tested: programmed high-rate therapy, delayed therapy, and conventional programming.
  • Primary endpoint was the first occurrence of inappropriate antitachycardia pacing or shocks.

Main Results:

  • High-rate therapy and delayed therapy significantly reduced the incidence of inappropriate therapy compared to conventional programming (HR 0.21 and 0.24, respectively).
  • Both novel programming strategies were associated with reductions in all-cause mortality (HR 0.45 and 0.56, respectively).
  • No significant differences in procedure-related adverse events were observed across the groups.

Conclusions:

  • Programming ICDs for tachyarrhythmias at 200 bpm or higher, or with prolonged delays at 170 bpm or higher, reduces inappropriate therapies.
  • These advanced ICD programming methods also demonstrate a significant reduction in all-cause mortality.
  • The findings support the adoption of optimized ICD programming for improved patient safety and survival.